Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Jim Cramer, the host of Mad Money, reflected on the uncertainty surrounding the year 2025, focusing on several macroeconomic ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

This has led to some interesting research findings of the potential benefits of using medical marijuana in helping to manage symptoms of diabetes. This article covers the benefits of medical marijuana ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...